Sense Target Edit Cancer

Gene circuit platform for next-generation cancer immunotherapy

Sense Target Edit Cancer

Gene circuit platform for next-generation cancer immunotherapy

Challenges & Solutions

Challenge

Poor efficacy and potency

SOLUTION

Local immunostimulatory combination expression

Challenge

Selectivity and specificity

SOLUTION

Multiple tumor-specific synthetic sensors

Challenge

Off-target
activity

SOLUTION

Increased safety with our logic gate circuit

Circuit-Bio Platform

Next Generation Cancer Treatment

Our company generates gene circuits that locally and accurately produce a combination of multiple immune-stimulating proteins (immunomodulators) that are exclusively expressed in targeted tumor cells. This technology transforms the cancer cells into ‘Trojan horses’, triggering a robust long-term anti-tumoral immune response, controlled by multiple synthetic cancer-specific sensors. Our unique approach enables adaptation of each of the circuit components to the patient.

Circuit-Bio Pipeline

Circuit-Bio’s technology is relevant to different types of cancer. Our pipeline focuses on the following indications with a high unmet need burden among men and women.

Circuits

Indications

Discovery

CTB-CRC213

CTB-CRC412

CTB-BC1617

COLON CANCER

COLON CANCER

BREAST CANCER

Circuits

Indications

Discovery

CTB-CRC213

CTB-CRC412

CTB-BC1617

COLON

COLON

BREAST

Circuit-Bio DNA

Meet Our Team

Nir Skalka Ph.D.​

Chief Scientific Officer (CSO)

Amit

Amit Shraga Ph.D.

Scientist
Synthetic biology
Bioinformatics

chen

Chen Shimoni MSc.

Scientist
Cancer
immunology

Konstantin Rozenberg Ph.D.

Scientist
Discovery Platform

Inbar Shteinberg MSc.

Scientist
Discovery Platform

Join Our Team

We are always looking for the best people to work with us…

Circuit-Bio is a synthetic biology company developing an innovative unique platform of logical gene circuits for cancer immunotherapy, established in the biotech accelerator FutuRx in August 2020. The company’s platform focuses on generating gene circuits able to produce a combination of multiple immune-stimulating proteins exclusively expressed in targeted tumor cells.

Contact

Join Our Team

Please fill in the form below and we will contact you soon.
Skip to content